• Je něco špatně v tomto záznamu ?

Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival

M. Jakubíková, M. Týblová, A. Tesař, M. Horáková, D. Vlažná, I. Ryšánková, I. Nováková, K. Dolečková, P. Dušek, J. Piťha, S. Voháňka, J. Bednařík

. 2021 ; 28 (10) : 3418-3425. [pub] 20210625

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21024910

Grantová podpora
ID 870177 European Reference Network for Neuromuscular Diseases
GIP-20-L-14-212 Všeobecná Fakultní Nemocnice v Praze, General University Hospital
FNBr 65269705 Ministerstvo Zdravotnictví Ceské Republiky
MUNI/A/1600/2020 Masarykova Univerzita

BACKGROUND AND PURPOSE: Myasthenia gravis (MG) patients could be a vulnerable group in the pandemic era of coronavirus 2019 (COVID-19) mainly due to respiratory muscle weakness, older age and long-term immunosuppressive treatment. We aimed to define factors predicting the severity of COVID-19 in MG patients and risk of MG exacerbation during COVID-19. METHODS: We evaluated clinical features and outcomes after COVID-19 in 93 MG patients. RESULTS: Thirty-five patients (38%) had severe pneumonia and we recorded 10 deaths (11%) due to COVID-19. Higher forced vital capacity (FVC) values tested before COVID-19 were shown to be protective against severe infection (95% CI 0.934-0.98) as well as good control of MG measured by the quantified myasthenia gravis score (95% CI 1.047-1.232). Long-term chronic corticosteroid treatment worsened the course of COVID-19 in MG patients (95% CI 1.784-111.43) and this impact was positively associated with dosage (p = 0.005). Treatment using azathioprine (95% CI 0.448-2.935), mycophenolate mofetil (95% CI 0.91-12.515) and ciclosporin (95% CI 0.029-2.212) did not influence the course of COVID-19. MG patients treated with rituximab had a high risk of death caused by COVID-19 (95% CI 3.216-383.971). Exacerbation of MG during infection was relatively rare (15%) and was not caused by remdesivir, convalescent plasma or favipiravir (95% CI 0.885-10.87). CONCLUSIONS: As the most important predictors of severe COVID-19 in MG patients we identified unsatisfied condition of MG with lower FVC, previous long-term corticosteroid treatment especially in higher doses, older age, the presence of cancer, and recent rituximab treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21024910
003      
CZ-PrNML
005      
20250205145509.0
007      
ta
008      
211013s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/ene.14951 $2 doi
035    __
$a (PubMed)34080271
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Jakubíková, Michala $u Department of Neurology and Center for Clinical Neuroscience, Charles University in Prague, First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic
245    10
$a Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival / $c M. Jakubíková, M. Týblová, A. Tesař, M. Horáková, D. Vlažná, I. Ryšánková, I. Nováková, K. Dolečková, P. Dušek, J. Piťha, S. Voháňka, J. Bednařík
520    9_
$a BACKGROUND AND PURPOSE: Myasthenia gravis (MG) patients could be a vulnerable group in the pandemic era of coronavirus 2019 (COVID-19) mainly due to respiratory muscle weakness, older age and long-term immunosuppressive treatment. We aimed to define factors predicting the severity of COVID-19 in MG patients and risk of MG exacerbation during COVID-19. METHODS: We evaluated clinical features and outcomes after COVID-19 in 93 MG patients. RESULTS: Thirty-five patients (38%) had severe pneumonia and we recorded 10 deaths (11%) due to COVID-19. Higher forced vital capacity (FVC) values tested before COVID-19 were shown to be protective against severe infection (95% CI 0.934-0.98) as well as good control of MG measured by the quantified myasthenia gravis score (95% CI 1.047-1.232). Long-term chronic corticosteroid treatment worsened the course of COVID-19 in MG patients (95% CI 1.784-111.43) and this impact was positively associated with dosage (p = 0.005). Treatment using azathioprine (95% CI 0.448-2.935), mycophenolate mofetil (95% CI 0.91-12.515) and ciclosporin (95% CI 0.029-2.212) did not influence the course of COVID-19. MG patients treated with rituximab had a high risk of death caused by COVID-19 (95% CI 3.216-383.971). Exacerbation of MG during infection was relatively rare (15%) and was not caused by remdesivir, convalescent plasma or favipiravir (95% CI 0.885-10.87). CONCLUSIONS: As the most important predictors of severe COVID-19 in MG patients we identified unsatisfied condition of MG with lower FVC, previous long-term corticosteroid treatment especially in higher doses, older age, the presence of cancer, and recent rituximab treatment.
650    _2
$a senioři $7 D000368
650    12
$a COVID-19 $x terapie $7 D000086382
650    12
$a koronavirové infekce $7 D018352
650    _2
$a lidé $7 D006801
650    _2
$a pasivní imunizace $7 D007116
650    12
$a myasthenia gravis $x komplikace $x farmakoterapie $x epidemiologie $7 D009157
650    _2
$a SARS-CoV-2 $7 D000086402
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Týblová, Michaela $u Department of Neurology and Center for Clinical Neuroscience, Charles University in Prague, First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Tesař, Adam $u Department of Neurology and Center for Clinical Neuroscience, Charles University in Prague, First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic $u Institute of Biophysics and Informatics of the First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Horáková, Magda $u Department of Neurology, ERN EURO-NMD Center, University Hospital Brno, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Vlažná, Daniela $u Department of Neurology, ERN EURO-NMD Center, University Hospital Brno, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Rehabilitation, University Hospital Brno, Brno, Czech Republic $7 xx0254852
700    1_
$a Ryšánková, Irena $u Department of Neurology and Center for Clinical Neuroscience, Charles University in Prague, First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic $7 xx0229048
700    1_
$a Nováková, Iveta $u Department of Neurology and Center for Clinical Neuroscience, Charles University in Prague, First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Dolečková, Kristýna $u Department of Neurology and Center for Clinical Neuroscience, Charles University in Prague, First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic $7 xx0328861
700    1_
$a Dušek, Pavel $u Department of Neurology and Center for Clinical Neuroscience, Charles University in Prague, First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Piťha, Jiří $u Department of Neurology and Center for Clinical Neuroscience, Charles University in Prague, First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Voháňka, Stanislav $u Department of Neurology, ERN EURO-NMD Center, University Hospital Brno, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Bednařík, Josef $u Department of Neurology, ERN EURO-NMD Center, University Hospital Brno, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
773    0_
$w MED00001629 $t European journal of neurology $x 1468-1331 $g Roč. 28, č. 10 (2021), s. 3418-3425
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34080271 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20250205145506 $b ABA008
999    __
$a ok $b bmc $g 1714107 $s 1145417
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 28 $c 10 $d 3418-3425 $e 20210625 $i 1468-1331 $m European journal of neurology $n Eur J Neurol $x MED00001629
GRA    __
$a ID 870177 $p European Reference Network for Neuromuscular Diseases
GRA    __
$a GIP-20-L-14-212 $p Všeobecná Fakultní Nemocnice v Praze, General University Hospital
GRA    __
$a FNBr 65269705 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a MUNI/A/1600/2020 $p Masarykova Univerzita
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace